Spikevax

Spikevax. It is a messenger RNA (mRNA) vaccine developed for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus. The vaccine, with the INN elasomeran, was developed by the American biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases. It received its first Emergency Use Authorization from the U.S. Food and Drug Administration in December 2020 and has since gained full approval in multiple countries, playing a central role in global pandemic response efforts.

Medical uses

Spikevax is authorized for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six months and older. Initial vaccination typically involves a primary series, with recommendations for subsequent booster doses to address waning immunity and emerging SARS-CoV-2 variants such as Omicron variant. The Centers for Disease Control and Prevention and the World Health Organization provide guidelines on its use, including specific recommendations for immunocompromised individuals. Its administration is via intramuscular injection, and it is not indicated for the treatment of active COVID-19 infection.

Adverse effects

Common adverse reactions are generally mild to moderate and include injection site pain, fatigue, headache, myalgia, arthralgia, chills, nausea, vomiting, and axillary swelling or tenderness. Serious adverse events are rare but can include myocarditis and pericarditis, with observed risks higher in adolescent and young adult males following the second dose. Other reported serious events include anaphylaxis and Guillain–Barré syndrome. Safety monitoring is conducted through systems like the Vaccine Adverse Event Reporting System and the European Medicines Agency's EudraVigilance.

Pharmacology

Spikevax utilizes a nucleoside-modified messenger RNA (modRNA) sequence that encodes the spike protein of the SARS-CoV-2 virus. The mRNA is encapsulated in lipid nanoparticles that facilitate delivery into host cells, primarily at the injection site and local draining lymph nodes. Once inside the cytoplasm, cellular ribosomes translate the mRNA to produce the viral spike protein, which is then displayed on the cell surface, triggering a protective adaptive immune response involving both B cells and T cells. This response generates neutralizing antibodies and cellular immunity against future SARS-CoV-2 infection.

History and development

The development of Spikevax began in January 2020 following the publication of the SARS-CoV-2 genetic sequence by researchers in China. Scientists at Moderna and the Vaccine Research Center at the National Institutes of Health rapidly designed the mRNA-1273 sequence. The vaccine entered clinical trials with unprecedented speed, with Phase I clinical trial results published in *The New England Journal of Medicine*. The pivotal Phase III clinical trial, known as the COVE trial, demonstrated high efficacy. Regulatory milestones included an Emergency Use Authorization from the U.S. Food and Drug Administration in December 2020 and full approval (marketed as Spikevax) for adults in January 2022. Its development was supported by Operation Warp Speed.

Society and culture

The deployment of Spikevax was a landmark event in the COVID-19 pandemic, involving complex logistics for cold-chain distribution due to its storage requirements. It was subject to global vaccine equity debates, with initiatives like COVAX aiming to improve access. The vaccine's role was highlighted in public health campaigns led by figures like Anthony Fauci and organizations including the World Health Organization. Its development also influenced intellectual property discussions, with calls for a TRIPS waiver to facilitate broader manufacturing. The name "Spikevax" was adopted following full regulatory approval in several markets, including the European Union and the United States.

Category:RNA vaccines Category:Moderna Category:COVID-19 pandemic